Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ZEJULA
- ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
- SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
- Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
- Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
- Combination Therapy in Cancers With Mutations in DNA Repair Genes
- Reirradiation and Niraparib in Patients With Recurrent Glioblastoma
- Personalized Medicine for Advanced Biliary Cancer Patients
- Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
- Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
- Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency
- Niraparib Efficacy in Patient With Unresectable Mesothelioma
- Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy
- Niraparib In Recurrent LDH 1/2 Gliomas
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
- Niraparib in High-grade Endometrial Cancer Trial
- Niraparib for the Treatment of Leiomyosarcoma
- Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
- Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
- Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
- Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
- Niraparib in Tumors Metastatic to the CNS
- A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
- Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
- Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
- Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
- LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
- Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
- Niraparib + TSR042 In BRCA Mutated Breast Cancer
- Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
- Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
- Niraparib + Dostarlimab + RT in Pancreatic Cancer
- A Study of Niraparib in Patients With Relapsed Ovarian Cancer
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
- Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
- Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting
- Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)
- Niraparib/TTFields in GBM
- A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
- Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
- Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
- Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
- Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer
- Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy
- CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients
- Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
- Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer)
- A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
- Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
- Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
- Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix
- A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
- Niraparib in Patients With Pancreatic Cancer
- A Study to Evaluate the Efficacy and Safety of Niraparib Novel Treatment Combinations in Participants With Recurrent Ovarian Cancer
- Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
- Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer
- A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
- Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
- Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
- PEN-866 in Patients With Advanced Solid Malignancies
- A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Clinical trials list
click for details